Cargando…

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes

Diabetic patients are at particular risk of severe COVID-19. Human dipeptidyl peptidase-4 (DPP-4) is a membrane-bound aminopeptidase that regulates insulin release by inactivating incretin. DPP-4 inhibitors (DPP-4is) are therefore used as oral anti-diabetic drugs to restore normal insulin levels. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nag, Snehasish, Mandal, Samanwita, Mukherjee, Oindrila, Mukherjee, Suprabhat, Kundu, Rakesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096336/ https://www.ncbi.nlm.nih.gov/pubmed/37064327 http://dx.doi.org/10.2217/fvl-2022-0112

Ejemplares similares

Neutralizing antibody: a savior in the Covid-19 disease
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Toll-like receptor 4 in COVID-19: friend or foe?
por: Mukherjee, Suprabhat
Publicado: (2022)

Chemotherapy vs. Immunotherapy in combating nCOVID19: An update
por: Choudhury, Abhigyan, et al.
Publicado: (2021)

Nucleotides: saviors of the cell
por: Williams, Ruth
Publicado: (2006)

Idiotype/anti-idiotype antibodies: as a glorious savior in COVID-19 pandemics
por: Naveed, Ahsan, et al.
Publicado: (2021)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
por: Du, Hengzhi, et al.
Publicado: (2020)

Family Caregiver: The Forgotten Savior
por: Sadat Hejazi, Sima, et al.
Publicado: (2021)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
por: Krejner-Bienias, Alicja, et al.
Publicado: (2021)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Complement in Pancreatic Disease—Perpetrator or Savior?
por: Bettac, Lucas, et al.
Publicado: (2017)

Magill forceps: A savior in bronchoscopy
por: Bansal, Teena, et al.
Publicado: (2017)

Kugel’s Artery: Silent Bystander or Savior?
por: Narh, Joshua T, et al.
Publicado: (2021)

Healthcare professionals are “corona saviors” not “warriors”
por: Kumar, Rajesh, et al.
Publicado: (2022)

DPP-4 inhibitors and severe course of illness in patients with COVID-19
por: Bouhanick, Béatrice, et al.
Publicado: (2021)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

CPR in COVID-19: Should We Use the PAPR to Keep the Savior Safe?
por: Saran, Sai
Publicado: (2021)

Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance
por: Mathew, Nimitha R., et al.
Publicado: (2020)

Hypertrophied crista terminalis–The great masquerader and savior
por: Ahmed, A. Shaheer, et al.
Publicado: (2020)

Novel Therapeutic Savior for Osteosarcoma: The Endorsement of Ferroptosis
por: Qiu, Cheng, et al.
Publicado: (2022)

Editorial: Seafood: nutrition savior or safety hazard?
por: Sousa, Sara, et al.
Publicado: (2023)

Abscisic Acid—Enemy or Savior in the Response of Cereals to Abiotic and Biotic Stresses?
por: Gietler, Marta, et al.
Publicado: (2020)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
por: Rhee, Sang Youl, et al.
Publicado: (2021)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
por: Schweizer, Anja, et al.
Publicado: (2013)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Is Lymphadenectomy a Predictor or Savior for Patients with Gastric Cancer?
por: Takeuchi, Hiroya, et al.
Publicado: (2010)

Bilateral ESP block: Savior in patient with Crouzon syndrome
por: Arun, Nidhi, et al.
Publicado: (2022)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022)

Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths
por: Strollo, Rocky, et al.
Publicado: (2021)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure
por: Castagnoli, Lorenzo, et al.
Publicado: (2020)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
por: Thomas, Merlin C., et al.
Publicado: (2016)

Anti-trafficking saviors: Celebrity, slavery, and branded activism
por: Heynen, Robert, et al.
Publicado: (2021)

Hydrochlorothiazide: A savior to the heart or a foe to the skin?
por: Kumar, Ayush, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t67kmfgm82sochvk4bmdbqf6sb